Disclosure Of First-Time Adoption [Text Block]

Xbrane Biopharma - Filing #689992

Concept As at
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
As at
2021-12-31
As at
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
As at
2020-12-31
As at
2020-12-31
As at
2020-12-31
As at
2020-12-31
As at
2020-12-31
Disclosure of first-time adoption [text block]
Disclosure of comparative information prepared under previous GAAP [text block]
Disclosure of comparative information prepared under previous GAAP [abstract]
Disclosure of comparative information prepared under previous GAAP [line items]
Equity
424 888 SEK
1 294 227 SEK
885 827 SEK
6 166 SEK
10 322 SEK
713 313 SEK
431 741 SEK
5 165 SEK
5 614 SEK
1 134 276 SEK
524 938 SEK
4 977 SEK
3 945 SEK
773 724 SEK
257 709 SEK
Comprehensive income
SEK
167 356 SEK
172 513 SEK
SEK
5 157 SEK
SEK
1 220 SEK
SEK
187 156 SEK
188 376 SEK
Profit (loss)
172 513 SEK
172 513 SEK
188 376 SEK
188 376 SEK

Talk to a Data Expert

Have a question? We'll get back to you promptly.